Citigroup Downgrades Catalyst Pharmaceuticals to Neutral, Lowers Price Target to $31.5

Benzinga Newsdesk www.benzinga.com Negative 92.2%

Neg 92.2% Neu 0% Pos 0%

Citigroup analyst Samantha Semenkow downgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) from Buy to Neutral and lowers the price target from $35 to $31.5.